Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 143-168 |
| Number of pages | 26 |
| Journal | European Journal of Heart Failure |
| Volume | 24 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2022 |
Keywords
- cardiology
- heart failure
- human
- risk factor
- Cardiology
- Heart Failure
- Humans
- Risk Factors
Fingerprint
Dive into the research topics of 'Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: European Journal of Heart Failure, Vol. 24, No. 1, 2022, p. 143-168.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology
AU - Piepoli, M.F.
AU - Adamo, M.
AU - Barison, A.
AU - Bestetti, R.B.
AU - Biegus, J.
AU - Böehm, M.
AU - Butler, J.
AU - Carapetis, J.
AU - Ceconi, C.
AU - Chioncel, O.
AU - Coats, A.
AU - Crespo-Leiro, M.G.
AU - de Simone, G.
AU - Drexel, H.
AU - Emdin, M.
AU - Farmakis, D.
AU - Halle, M.
AU - Heymans, S.
AU - Jaarsma, T.
AU - Jankowska, E.
AU - Lainscak, M.
AU - Lam, C.S.P.
AU - Løchen, M.-L.
AU - Lopatin, Y.
AU - Maggioni, A.
AU - Matrone, B.
AU - Metra, M.
AU - Noonan, K.
AU - Pina, I.
AU - Prescott, E.
AU - Rosano, G.
AU - Seferovic, P.M.
AU - Sliwa, K.
AU - Stewart, S.
AU - Uijl, A.
AU - Vaartjes, I.
AU - Vermeulen, R.
AU - Monique Verschuren, W.M.
AU - Volterrani, M.
AU - Von Heahling, S.
AU - Hoes, A.
N1 - Cited By :7 Export Date: 12 July 2022 CODEN: EJHFF Correspondence Address: Piepoli, M.F.; Cardiac Unit, Italy; email: m.piepoli@gmail.com Funding details: Abbott Laboratories Funding details: Amgen Funding details: Pfizer Funding details: AstraZeneca Funding details: Bayer Funding details: Merck Funding details: Novartis Funding details: Roche Funding details: Sanofi Funding details: Medtronic Funding details: Boehringer Ingelheim Funding details: Boston Scientific Corporation, BSC Funding details: Cytokinetics, CYTK Funding details: MyoKardia Funding details: National Medical Research Council, NMRC Funding details: Deutsche Forschungsgemeinschaft, DFG, 322900939, TTR 219 Funding details: Novo Nordisk Funding details: Vifor Pharma Funding details: Servier Funding details: Menarini Group Funding text 1: M.B. reports fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Medtronic, Novartis, ReCor, Servier, and Vifor and is supported by the Deutsche Forschungsgemeinschaft (DFG, TTR 219, S‐01, project ID 322900939). M.G.C.‐L. received research grants to my institution and personal fees for lectures or advisory board meetings from CIBERCV. Novartis, AstraZeneca, Vifor, Pfizer, Astellas Pharma. None of them related to the present manuscript. S.H. has received personal fees for scientific advice to AstraZeneca, Cellprothera, and Merck; unrestricted research grant from Pfizer. C.S.P.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, and Vifor Pharma; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott Diagnostics, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Biofourmis, Boehringer Ingelheim, Boston Scientific, Corvia Medical, Cytokinetics, Darma Inc., Us2.ai, JanaCare, Janssen Research & Development LLC, Medtronic, Menarini Group, Merck, MyoKardia, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics, Sanofi, Stealth BioTherapeutics, The Corpus, Vifor Pharma, and WebMD Global LLC; and serves as co‐founder and non‐executive director of Us2.ai. A.M. received personal fees for the participation in committees of studies sponsored by Bayer, Fresenius, Novartis outside the present work. M.F.P. received research grants to his institution and personal fees for lectures or advisory board meetings from Novartis, Vifor, AstraZeneca, and CHF solution. None of them related to the present manuscript. P.M.S. received Medtronic honorarium for lecture, Abbott honorarium for lecture, Servier honorarium for lecture, Astra Zeneca honorarium for lecture, Respicardia honorarium for lecture, Boehringer Ingelheimconsultancy agreement and honorarium for lecture, Novartis consultancy agreement and honorarium for lecture, Vifor Pharma consultancy agreement. All other authors declared no conflict of interest. Conflict of interest: References: Groenewegen, A., Rutten, F.H., Mosterd, A., Hoes, A.W., Epidemiology of heart failure (2020) Eur J Heart Fail, 22, pp. 1342-1356; Uijl, A., Koudstaal, S., Direk, K., Denaxas, S., Groenwold, R., Banerjee, A., Hoes, A.W., Asselbergs, F.W., Risk factors for incident heart failure in age- and sex- specific strata: a population-based cohort using linked electronic health records (2019) Eur J Heart Fail, 21, pp. 1197-1206; Del Gobbo, L.C., Kalantarian, S., Imamura, F., Lemaitre, R., Siscovick, D.S., Psaty, B.M., Mozaffarian, D., Contribution of major lifestyle risk factors for incident heart failure in older adults: the Cardiovascular Health Study (2015) JACC Heart Fail., 3, pp. 520-528; Piepoli, M.F., Hoes, A.W., Agewall, S., Albus, C., Brotons, C., Catapano, A.L., Cooney, M.T., Binno, S., 2016 European Guidelines on cardiovascular disease prevention in clinical practice (2016) Eur Heart J, 37, pp. 2315-2381; Mach, F., Baigent, C., Catapano, A.L., Koskinas, K.C., Casula, M., Badimon, L., Chapman, M.J., Wiklund, O., 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2020) Eur Heart J, 41, pp. 111-188; Dunlay, S.M., Weston, S.A., Jacobsen, S.J., Roger, V.L., Risk factors for heart failure: a population- based case-control study (2009) Am J Med, 122, pp. 1023-1028; Vasan, R.S., Beiser, A., Seshadri, S., Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study (2002) JAMA, 287, pp. 1003-1010; Levy, D., Larson, M.G., Vasan, R.S., Kannel, W.B., Ho, K.K., The progression from hypertension to congestive heart failure (1996) JAMA, 275, pp. 1557-1562; Wilhelmsen, L., Rosengren, A., Eriksson, H., Lappas, G., Heart failure in the general population of men--morbidity, risk factors and prognosis (2001) J Intern Med, 249, pp. 253-256; Avery, C.L., Loehr, L.R., Baggett, C., Chang, P.P., Kucharska-Newton, A.M., Matsushita, K., Rosamond, W.D., Heiss, G., The population burden of heart failure attributable to modifiable risk factors: the ARIC (Atherosclerosis Risk in Communities) study (2012) J Am Coll Cardiol, 60, pp. 1640-1646; Sciarretta, S., Palano, F., Tocci, G., Baldini, R., Volpe, M., Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk (2011) Arch Intern Med, 171, pp. 384-394; Bangalore, S., Wild, D., Parkar, S., Kukin, M., Messerli, F.H., Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis (2008) J Am Coll Cardiol, 52, pp. 1062-1072; Shah, A., Langenberg, C., Rapsomaniki, E., Denaxas, S., Pujades-Rodriguez, M., Gale, C.P., Deanfield, J., Hemingway, H., Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people (2015) Lancet Diabetes Endocrinol, 3, pp. 105-113; McAllister, D.A., Read, S.H., Kerssens, J., Livingstone, S., McGurnaghan, S., Jhund, P., Petrie, J., Wild, S.H., Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus (2018) Circulation, 138, pp. 2774-2786; Shah, S.J., Lam, C.S.P., Svedlund, S., Saraste, A., Hage, C., Tan, R., Beussink-Nelson, L., Lund, L., Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF (2018) Eur Heart J, 39, pp. 3439-3450; Devereux, R.B., Roman, M.J., Paranicas, M., Lee, E.T., Welty, T.K., Fabsitz, R.R., Robbins, D., Howard, B.V., (2000) Circulation, 101, pp. 2271-2276. , O'Grady MJ,, Impact of diabetes on cardiac structure and function the strong heart study; Van Melle, J.P., Bot, M., de Jonge, P., de Boer, R.A., van Veldhuisen, D.J., Whooley, M.A., Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study (2010) Diabetes Care, 33, pp. 2084-2089; Rosano, G.M., Vitale, C., Seferovic, P., Heart failure in patients with diabetes mellitus (2017) Card Fail Rev, 3, pp. 52-55; Gerstein, H.C., Miller, M.E., Byington, R.P., Goff, D.C., Jr., Bigger, J.T., Buse, J.B., Cushman, W.C., Friedewald, W.T., Effects of intensive glucose lowering in type 2 diabetes (2008) N Engl J Med, 358, pp. 2545-2559; Komajda, M., McMurray, J.J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Pocock, S.J., Curtis, P.S., Home, P.D., Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial (2010) Eur Heart J, 31, pp. 824-831; Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Inzucchi, S.E., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (2015) N Engl J Med, 373, pp. 2117-2128; Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Matthews, D.R., Canagliflozin and cardiovascular and renal events in type 2 diabetes (2017) N Engl J Med, 377, pp. 644-657; Wiviott, S.D., Raz, I., Bonaca, M.P., Mosenzon, O., Kato, E.T., Cahn, A., Silverman, M.G., Sabatine, M.S., Dapagliflozin and cardiovascular outcomes in type 2 diabetes (2019) N Engl J Med, 380, pp. 347-357; Cannon, C.P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., McGuire, D.K., Cardiovascular outcomes with ertugliflozin in type 2 diabetes (2020) N Engl J Med, 383, pp. 1425-1435; Perkovic, V., Jardine, M.J., Neal, B., Bompoint, S., Heerspink, H.J.L., Charytan, D.M., Edwards, R., Mahaffey, K.W., Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (2019) N Engl J Med, 380, pp. 2295-2306; Heerspink, H.J.L., Stefánsson, B.V., Correa-Rotter, R., Chertow, G.M., Greene, T., Hou, F.F., Mann, J.F.E., Wheeler, D.C., Dapagliflozin in patients with chronic kidney disease (2020) N Engl J Med, 383, pp. 1436-1446; Zelniker, T.A., Wiviott, S.D., Raz, I., Im, K., Goodrich, E.L., Bonaca, M.P., Mosenzon, O., Sabatine, M.S., SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials (2019) Lancet, 393, pp. 31-39; Rydén, L., Grant, P.J., Anker, S.D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Xuereb, R.G., ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) (2020) Eur Heart J, 41, pp. 255-323; Seferović, P.M., Coats, A.J.S., Ponikowski, P., Filippatos, G., Huelsmann, M., Jhund, P.S., Polovina, M.M., Rosano, G.M.C., European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure (2020) Eur J Heart Fail, 22, pp. 196-213; Seferović, P.M., Fragasso, G., Petrie, M., Mullens, W., Ferrari, R., Thum, T., Bauersachs, J., Gmc, R., Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology (2020) Eur J Heart Fail, 22, pp. 1495-1503; Seferovic, P.M., Ponikowski, P., Anker, S.D., Bauersachs, J., Chioncel, O., Jgf, C., de Boer, R.A., Coats, A.J., Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology (2019) Eur J Heart Fail, 21, pp. 1169-1186. , McDonagh T; Inzucchi, S.E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Lachin, J.M., How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial (2018) Diabetes Care, 41, pp. 356-363; Green, J.B., Bethel, M.A., Armstrong, P.W., Buse, J.B., Engel, S.S., Garg, J., Josse, R., Holman, R.R., Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes (2015) N Engl J Med, 373, pp. 232-242; McGuire, D.K., Alexander, J.H., Johansen, O.E., Perkovic, V., Rosenstock, J., Cooper, M.E., Wanner, C., Marx, N., Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA (2019) Circulation, 139, pp. 351-361; Zannad, F., Cannon, C.P., Cushman, W.C., Bakris, G.L., Menon, V., Perez, A.T., Fleck, P.R., White, W.B., Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial (2015) Lancet, 385, pp. 2067-2076; Scirica, B.M., Braunwald, E., Raz, I., Cavender, M.A., Morrow, D.A., Jarolim, P., Udell, J.A., Bhatt, D.L., Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial (2014) Circulation, 130, pp. 1579-1588; McMurray, J.J.V., Ponikowski, P., Bolli, G.B., Lukashevich, V., Kozlovski, P., Kothny, W., Lewsey, J.D., Krum, H., Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial (2018) JACC Heart Fail, 6, pp. 8-17; Pfeffer, M.A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Køber, L.V., Lawson, F.C., Tardif, J.C., Lixisenatide in patients with type 2 diabetes and acute coronary syndrome (2015) N Engl J Med, 373, pp. 2247-2257; Holman, R.R., Bethel, M.A., Mentz, R.J., Thompson, V.P., Lokhnygina, Y., Buse, J.B., Chan, J.C., Hernandez, A.F., Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (2017) N Engl J Med, 377, pp. 1228-1239; Husain, M., Morten Donsmark, M., Kathleen Dungan, K., Freddy, G., Eliaschewitz, F.G., Denise, R., Franco, D.R., Mette Thomsen, M., Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes (2019) N Engl J Med, 381, pp. 841-851. , Andreas L. Birkenfeld AL,, Tack CJ, M.D; Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., Nissen, S.E., Buse, J.B., Liraglutide and cardiovascular outcomes in type 2 diabetes (2016) N Engl J Med, 375, pp. 311-322. , Pocock; Hernandez, A.F., Green, J.B., Janmohamed, S., Granger, C.B., Jones, N.P., Leiter, L.A., Rosenberg, A.E., Del Prato, S., Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial (2018) Lancet, 392, pp. 1519-1529. , D'Agostino RB Sr; Berl, T., Hunsicker, L.G., Lewis, J.B., Pfeffer, M.A., Porush, J.G., Rouleau, J.L., Drury, P.L., Lewis, E.J., Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy (2003) Ann Intern Med, 138, pp. 542-549; Rawshani, A., Rawshani, A., Franzén, S., Sattar, N., Eliasson, B., Svensson, A.M., Zethelius, B., Gudbjörnsdottir, S., Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes (2018) N Engl J Med, 379, pp. 633-644; Kosiborod, M., Lam, C.S.P., Kohsaka, S., Kim, D.J., Karasik, A., Shaw, J., Tangri, N., Magliano, D., Cardiovascular events associated with SGLT-2 inhibitors versus other glucoselowering drugs: the CVD-REAL 2 study (2018) J Am Coll Cardiol, 71, pp. 2628-2639; Patorno, E., Pawar, A., Franklin, J.M., Najafzadeh, M., Déruaz-Luyet, A., Brodovicz, K.G., Sambevski, S., Schneeweiss, S., Empagliflozin and the risk of heart failure hospitalization in routine clinical care (2019) Circulation, 139, pp. 2822-2830; Pandey, A., Garg, S., Khunger, M., Darden, D., Ayers, C., Kumbhani, D.J., Mayo, H.G., Berry, J.D., Dose-response relationship between physical activity and risk of heart failure: a meta-analysis (2015) Circulation, 132, pp. 1786-1794; He, J., Ogden, L.G., Bazzano, L.A., Vupputuri, S., Loria, C., Whelton, P.K., Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study (2001) Arch Intern Med, 161, pp. 996-1002; Agha, G., Loucks, E.B., Tinker, L.F., Waring, M.E., Michaud, D.S., Foraker, R.E., Li, W., Eaton, C.B., Healthy lifestyle and decreasing risk of heart failure in women: the Women's, Health Initiative observational study (2014) J Am Coll Cardiol, 64, pp. 1777-1785; Velagaleti, R.S., Massaro, J., Vasan, R.S., Robins, S.J., Kannel, W.B., Levy, D., Relations of lipid concentrations to heart failure incidence: the Framingham Heart Study (2009) Circulation, 120, pp. 2345-2351; Ebong, I.A., Goff, D.C., Jr., Rodriguez, C.J., Chen, H., Sibley, C.T., Bertoni, A.G., Association of lipids with incident heart failure among adults with and without diabetes mellitus: Multiethnic Study of Atherosclerosis (2013) Circ Heart Fail, 6, pp. 371-378; Preiss, D., Campbell, R.T., Murray, H.M., Ford, I., Packard, C.J., Sattar, N., Rahimi, K., McMurray, J.J., The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials (2015) Eur Heart J, 36, pp. 1536-1546; Kenchaiah, S., Evans, J.C., Levy, D., Wilson, P.W., Benjamin, E.J., Larson, M.G., Kannel, W.B., Vasan, R.S., Obesity and the risk of heart failure (2002) N Engl J Med, 347, pp. 305-313; Chen, X., Thunström, E., Hansson, P.O., Rosengren, A., Mandalenakis, Z., Zhong, Y., Ergatoudes, C., Fu, M., High prevalence of cardiac dysfunction or overt heart failure in 71-year-old men: A 21-year follow-up of “The Study of men born in 1943 (2020) Eur J Prev Cardiol, 27, pp. 717-725; Eaton, C.B., Pettinger, M., Rossouw, J., Martin, L.W., Foraker, R., Quddus, A., Liu, S., Klein, L., Risk factors for incident hospitalized heart failure with preserved versus reduced ejection fraction in a multiracial cohort of postmenopausal women (2016) Circ Heart Fail, 9; Alpert, M.A., Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome (2001) Am J Med Sci, 321, pp. 225-236; Marfella, R., Di Filippo, C., Portoghese, M., Barbieri, M., Ferraraccio, F., Siniscalchi, M., Cacciapuoti, F., Paolisso, G., (2009) J Lipid Res, 50, pp. 2314-2323. , D', Myocardial lipid accumulation in patients with pressure- overloaded heart and metabolic syndrome; Aimo, A., Castiglione, V., Borrelli, C., Saccaro, L.F., Franzini, M., Masi, S., Emdin, M., Giannoni, A., Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies (2020) Eur J Prev Cardiol, 27, pp. 494-510; Reddy, Y.N.V., Anantha-Narayanan, M., Obokata, M., Koepp, K.E., Erwin, P., Carter, R.E., Borlaug, B.A., Hemodynamic effects of weight loss in obesity: a systematic review and meta-analysis (2019) JACC Heart Fail, 7, pp. 678-687; Wang, Y., Tuomilehto, J., Jousilahti, P., Antikainen, R., Mähönen, M., Katzmarzyk, P.T., Hu, G., Lifestyle factors in relation to heart failure among Finnish men and women (2011) Circ Heart Fail, 4, pp. 607-612; Favuzzi, A.M.R., Venuti, A., Bruno, C., Nicolazzi, M.A., Fuorlo, M., Dajko, M., De Waure, C., Mancini, A., Hormonal deficiencies in heart failure with preserved ejection fraction: prevalence and impact on diastolic dysfunction: a pilot study (2020) Eur Rev Med Pharmacol Sci, 24, pp. 352-361; Bielecka-Dabrowa, A., Godoy, B., Suzuki, T., Banach, M., von Haehling, S., Subclinical hypothyroidism and the development of heart failure: an overview of risk and effects on cardiac function (2019) Clin Res Cardiol, 108, pp. 225-233; Rhee, S.S., Pearce, E.N., Update: Systemic diseases and the cardiovascular system (II). The endocrine system and the heart: a review Rev Esp Cardiol, 64, pp. 220-231; Guzzo-Merello, G., Segovia, J., Dominguez, F., Cobo-Marcos, M., Gomez-Bueno, M., Avellana, P., Millan, I., Garcia-Pavia, P., Natural history and prognostic factors in alcoholic cardiomyopathy (2015) JACC Heart Fail, 3, pp. 78-86; Larsson, S.C., Orsini, N., Wolk, A., Alcohol consumption and risk of heart failure: a dose-response meta-analysis of prospective studies (2015) Eur J Heart Fail, 17, pp. 367-373; Stockwell, T., Zhao, J., Panwar, S., Roemer, A., Naimi, T., Chikritzhs, T., Do “moderate” drinkers have reduced mortality risk? A systematic review and meta-analysis of alcohol consumption and all-cause mortality (2016) J Stud Alcohol Drugs, 77, pp. 185-198; Wood, A.M., Kaptoge, S., Butterworth, A.S., Willeit, P., Warnakula, S., Bolton, T., Paige, E., Danesh, J., Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies (2018) Lancet, 391, pp. 1513-1523. , Blazer DG 2nd; Ware, J.S., Amor-Salamanca, A., Tayal, U., Govind, R., Pascual-Figal, D.A., Nuñez, J., Guzzo-Merello, G., Garcia-Pavia, P., Genetic etiology for alcohol-induced cardiac toxicity (2018) J Am Coll Cardiol, 71, pp. 2293-2302. , Serrano I, Salazar-Mendiguchía J, García-Pinilla JM,, O'; Faris, R.F., Henein, M.Y., Coats, A.J., Influence of gender and reported alcohol intake on mortality in nonischemic dilated cardiomyopathy (2003) Heart Dis, 5, pp. 89-94; Pavan, D., Nicolosi, G.L., Lestuzzi, C., Burelli, C., Zardo, F., Zanuttini, D., Normalization of variables of left ventricular function in patients with alcoholic cardiomyopathy after cessation of excessive alcohol intake: an echocardiographic study (1987) Eur Heart J, 8, pp. 535-540; Golder, C., Gaziano, J.M., Should people with heart failure avoid alcohol? An evidence review | Nursing Times, 114, pp. 43-45. , Nursing Times, [online];, 3; Agarwal, S.K., Chambless, L.E., Ballantyne, C.M., Prediction of incident heart failure in general practice (2012) Circ Heart Fail, 5, pp. 422-429; Gopal, D.M., Kalogeropoulos, A.P., Georgiopoulou, V.V., Smith, A.L., Bauer, D.C., Newman, A.B., Kim, L., Butler, J., Cigarette smoking exposure and heart failure risk in older adults: the Health, Aging, and Body Composition Study (2012) Am Heart J, 164, pp. 236-242; Kamimura, D., Cain, L.R., Mentz, R.J., White, W.B., Blaha, M.J., DeFilippis, A.P., Fox, E.R., Hall, M.E., Cigarette smoking and incident heart failure: insights from the Jackson Heart Study (2018) Circulation, 137, pp. 2572-2582; Aune, D., Schlesinger, S., Norat, T., Riboli, E., Tobacco smoking and the risk of heart failure: A systematic review and meta-analysis of prospective studies (2019) Eur J Prev Cardiol, 26, pp. 279-288; Ambrose, J.A., Barua, S.R., The pathophysiology of cigarette smoking and cardiovascular disease: an update (2004) J Am Coll Cardiol, 43, pp. 1731-1737; Nadruz, W., Jr., Claggett, B., Gonçalves, A., Querejeta-Roca, G., Fernandes-Silva, M.M., Shah, A.M., Cheng, S., Solomon, S.D., Smoking and cardiac structure and function in the elderly: the ARIC Study (Atherosclerosis Risk in Communities) (2016) Circ Cardiovasc Imaging, 9; Moreira, H.T., Armstrong, A.C., Nwabuo, C.C., Vasconcellos, H.D., Schmidt, A., Sharma, R.K., Ambale-Venkatesh, B., Lima, J.A.C., Association of smoking and right ventricular function in middle age: CARDIA study (2020) Open Heart, 7; Hendriks, T., van Dijk, R., Alsabaan, N.A., van der Harst, P., Active tobacco smoking impairs cardiac systolic function Sci Rep, 10, p. 6608. , 2020; Rosen, B.D., Saad, M.F., Shea, S., Nasir, K., Edvardsen, T., Burke, G., Jerosch-Herold, M., Lima, J.A., Hypertension and smoking are associated with reduced regional left ventricular function in asymptomatic: individuals the Multi-Ethnic Study of Atherosclerosis (2006) J Am Coll Cardiol, 47, pp. 1150-1158; Son, Y.J., Lee, H.J., Association between persistent smoking after a diagnosis of heart failure and adverse health outcomes: A systematic review and meta-analysis (2020) Tob Induc Dis, 18, pp. 1-11; Kim, C.-Y., Paek, Y.-J., Seo, H.G., Kim, C.Y., Paek, Y.J., Gwan Seo, H., Cheong, Y.S., Lee, K., Dual use of electronic and conventional cigarettes is associated with higher cardiovascular risk factors in Korean men (2020) Sci Rep, 10, p. 1. , –10; Kavousi, M., Pisinger, C., Barthelemy, J.C., Smedt, D., Koskinas, K., Marques-Vidal, P., Panagiotakos, D., Løchen, M.L., Electronic cigarettes and health with special focus on cardiovascular effects: position paper of the European Association of Preventive Cardiology (EAPC) Eur J Prev Cardiol, , 2020. [Epub ahead of print]; Osei, A.D., Mirbolouk, M., Orimoloye, O.A., The association between e-cigarette use and asthma among never combustible cigarette smokers: behavioral risk factor surveillance system (BRFSS) 2016 & 2017 (2019) BMC Pulm Med, 19, p. 180; Rezk-Hanna, M., Benowitz, N.L., Cardiovascular effects of hookah smoking: potential implications for cardiovascular risk (2019) Nicotine Tob Res, 21, pp. 1151-1161; (2009) The State of the Drugs Problem in Europe. European Monitoring Centre for Drugs and Drug Addiction. Publications Office of the European Union, p. 99; Havakuk, O., Rezkalla, S.H., Kloner, R.A., The cardiovascular effects of cocaine (2017) J Am Coll Cardiol, 70, pp. 101-113; Qureshi, A.I., Suri, M.F., Guterman, L.R., Hopkins, L.N., Cocaine use and the likelihood of nonfatal myocardial infarction and stroke: data from the Third National Health and Nutrition Examination Survey (2001) Circulation, 103, pp. 502-506; Aquaro, G.D., Gabutti, A., Meini, M., Prontera, C., Pasanisi, E., Passino, C., Emdin, M., Lombardi, M., Silent myocardial damage in cocaine addicts (2011) Heart, 97, pp. 2056-2062; Hantson, P., Mechanisms of toxic cardiomyopathy (2019) Clin Toxicol (Phila), 57, pp. 1-9; Becker, A.E., Grinspoon, S.K., Klibanski, A., Herzog, D.B., Eating disorders (1999) N Engl J Med, 340, pp. 1092-1098; Totzek, M., Muncu, R.I., Mrotzek, S., Schadendorf, D., Rassaf, T., Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients (2018) Eur J Prev Cardiol, 25, pp. 482-494; Howden, E.J., Bigaran, A., Beaudry, R., Fraser, S., Selig, S., Foulkes, S., Antill, Y., La Gerche, A., Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients (2019) Eur J Prev Cardiol, 26, pp. 305-315; Zamorano, J.L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Suter, T.M., 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) (2016) Eur Heart J, 37, pp. 2768-2801; Aleman, B.M., van den Belt-Dusebout, A.W., De Bruin, M.L., van 't Veer MB, Baaijens MH, de Boer JP, Hart AA, Klokman WJ, Kuenen MA, Ouwens GM, Bartelink H, van Leeuwen FE. Late cardiotoxicity after treatment for Hodgkin lymphoma (2007) Blood, 109, pp. 1878-1886; Hooning, M.J., Botma, A., Aleman, B.M., Baaijens, M.H., Bartelink, H., Klijn, J.G., Long-term risk of cardiovascular disease in 10-year survivors of breast cancer (2007) J Natl Cancer Inst, 99, pp. 365-375. , TaylorCW, van Leeuwen FE, H; Chello, M., Mastroroberto, P., Romano, R., Zofrea, S., Bevacqua, I., Marchese, A.R., Changes in the proportion of types I and III collagen in the left ventricular wall of patients with post-irradiative pericarditis (1996) Cardiovasc Surg, 4, pp. 222-226; Veinot, J., Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases (1996) Hum Pathol, 27, pp. 766-773; Menezes, K.M., Wang, H., Hada, M., Saganti, P.B., Radiation matters of the heart: a mini review (2018) Front Cardiovasc Med, 5, p. 83; Heymans, S., Eriksson, U., Lehtonen, J., Cooper, L.T., Jr., The quest for new approaches in myocarditis and inflammatory cardiomyopathy (2016) J Am Coll Cardiol, 68, pp. 2348-2364; Ammirati, E., Frigerio, M., Adler, E.D., Basso, C., Birnie, D.H., Brambatti, M., Friedrich, M.G., Camici, P.G., Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document (2020) Circ Heart Fail, 13; Tschöpe, C., Cooper, L.T., Torre-Amione, G., Van Linthout, S., Management of myocarditis-related cardiomyopathy in adults (2019) Circ Res, 124, pp. 1568-1583; Caforio, A.L., Pankuweit, S., Arbustini, E., Basso, C., Gimeno-Blanes, J., Felix, S.B., Fu, M., Elliott, P.M., Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases (2013) Eur Heart J, 34, pp. 2636-2648. , 2648a–2648d; Wu, H.-H., Chang, Y.-Y., Kuo, S.-C., Chen, Y.-T., Influenza vaccination and secondary prevention of cardiovascular disease among Taiwanese elders—a propensity score-matched follow-up study (2019) PLoS One, 14; Kadoglou, N.P.E., Bracke, F., Simmers, T., Tsiodras, S., Parissis, J., Influenza infection and heart failure-vaccination may change heart failure prognosis? (2017) Heart Fail Rev, 22, pp. 329-336; Barison, A., Aimo, A., Castiglione, V., Arzilli, C., Lupón, J., Codina, P., Santiago-Vacas, E., Bayes-Genis, A., Cardiovascular disease and COVID-19: les liaisons dangereuses (2020) Eur J Prev Cardiol, 27, pp. 1017-1025; Zhang, Y., Coats, A.J.S., Zheng, Z., Adamo, M., Ambrosio, G., Anker, S.D., Butler, J., Metra, M., Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology (2020) Eur J Heart Fail, 22, pp. 941-956; Lindner, D., Fitzek, A., Bräuninger, H., Aleshcheva, G., Edler, C., Meissner, K., Scherschel, K., Westermann, D., Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases (2020) JAMA Cardiol, 5, pp. 1281-1285; Puntmann, V.O., Carerj, M.L., Wieters, I., Fahim, M., Arendt, C., Hoffmann, J., Shchendrygina, A., Nagel, E., Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19) (2020) JAMA Cardiol, 5, pp. 1265-1273; Bern, C., Chagas' disease (2015) N Engl J Med, 373, pp. 456-466; Marin-Neto, J.A., Cunha-Neto, E., Maciel, B.C., Simões, M.V., Pathogenesis of chronic Chagas heart disease (2007) Circulation, 115, pp. 1109-1123; Echeverría, L.E., Rojas, L.Z., Villamizar, M.C., Luengas, C., Chaves, A.M., Rodríguez, J.A., Campo, R., Franco, O.H., Echocardiographic parameters, speckle tracking, and brain natriuretic peptide levels as indicators of progression of indeterminate stage to Chagas cardiomyopathy (2020) Echocardiography, 37, pp. 429-438; Carapetis, J.R., McDonald, M., Wilson, N.J., Acute rheumatic fever (2005) Lancet, 366, pp. 155-168; Carapetis, J.R., Steer, A.C., Mulholland, E.K., Weber, M., The global burden of group A streptococcal diseases (2005) Lancet Infect Dis, 5, pp. 685-694; Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018) Lancet, 392, pp. 1789-1858; Xu, R., Wyber, R., (2019) How is group A Streptococcus transmitted from person to person? A systematic review. PROSPERO, , CRD42019138472; Robertson, K.A., Volmink, J.A., Mayosi, B.M., Antibiotics for the primary prevention of acute rheumatic fever: a meta-analysis (2005) BMC Cardiovasc Disord, 5, p. 11; Mota, C.C., Meira, Z.M., Graciano, R.N., Graciano, F.F., Araújo, F.D., Rheumatic fever prevention program: long-term evolution and outcomes (2015) Front Pediatr, 2, p. 141; Mirabel, M., Tafflet, M., Noël, B., Parks, T., Axler, O., Robert, J., Nadra, M., Jouven, X., Newly diagnosed rheumatic heart disease among indigenous populations in the Pacific (2015) Heart, 101, pp. 1901-1096; Carapetis, J.R., Ralph, A.P., How many doses make a difference? an analysis of secondary prevention of rheumatic fever and rheumatic heart disease (2018) J Am Heart Assoc, 7. , de Dassel JL, de Klerk N; Okello, E., Longenecker, C.T., Beaton, A., Kamya, M.R., Lwabi, P., Rheumatic heart disease in Uganda: predictors of morbidity and mortality one year after presentation (2017) BMC Cardiovasc Disord, 17, p. 20; (2001) WHO Study Group on Rheumatic Fever and Rheumatic Heart Disease (2001 : Geneva S, Organization WH. Rheumatic Fever and Rheumatic Heart Disease: Report of a WHO Expert Consultation. Geneva: WHO, , World Health Organization technical report series; 923. 2001; Carapetis, J.R., Beaton, A., Cunningham, M.W., Guilherme, L., Karthikeyan, G., Mayosi, B.M., Sable, C., Zühlke, L., Acute rheumatic fever and rheumatic heart disease (2016) Nat Rev Dis Primers, 2, p. 15084; Bowen, A., Currie, B., Katzenellenbogen, J., Marangou, J., Noonan, S., Ralph, A., Roberts, K., Wyber, R., The 2020 Australian Guideline for Prevention, Diagnosis and Management of Acute Rheumatic Fever and Rheumatic Heart Disease. RHD Australia, Menzies School of Health Research (2021) Med J Aust, 214, pp. 220-227; Ponikowski, P., Anker, S.D., Chua, T.P., Francis, D., Banasiak, W., Poole-Wilson, P.A., Coats, A.J., Piepoli, M., Oscillatory breathing patterns during wakefulness in patients with chronic heart failure: clinical implications and role of augmented peripheral chemosensitivity (1999) Circulation, 100, pp. 2418-2424; Emdin, M., Mirizzi, G., Giannoni, A., Poletti, R., Iudice, G., Bramanti, F., Passino, C., Prognostic significance of central apneas throughout a 24-hour period in patients with heart failure (2017) J Am Coll Cardiol, 70, pp. 1351-1364; Lanfranchi, P.A., Braghiroli, A., Bosimini, E., Mazzuero, G., Colombo, R., Donner, C.F., Giannuzzi, P., Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure (1999) Circulation, 99, pp. 1435-1440; Giannoni, A., Morelli, M., Francis, D., (2016), pp. 91-124. , Pathophysiology of ventral apneas in heart failure. In Emdin M, Giannoni A, Passino C, eds. The Breathless Heart - Apneas in Heart Failure. New York, NY Springer-Verlag; Bradley, T.D., Floras, J.S., Sleep apnea and heart failure: Part I: obstructive sleep apnea (2003) Circulation, 107, pp. 1671-1678; Lanfranchi, P.A., Somers, V.K., Braghiroli, A., Corra, U., Eleuteri, E., Giannuzzi, P., Central sleep apnea in left ventricular dysfunction: prevalence and implications for arrhythmic risk (2003) Circulation, 107, pp. 727-732; Gottlieb, D.J., Yenokyan, G., Newman, A.B., Connor, G.T., Punjabi, N.M., Quan, S.F., Redline, S., Shahar, E., Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study (2010) Circulation, 122, pp. 352-360. , O'; Holt, A., Bjerre, J., Zareini, B., Koch, H., Tønnesen, P., Gislason, G.H., Nielsen, O.W., Lamberts, M., Sleep apnea, the risk of developing heart failure, and potential benefits of continuous positive airway pressure (CPAP) therapy (2018) J Am Heart Assoc, 7; (2016) Ambient air pollution: A global assessment of exposure and burden of disease, , https://apps.who.int/iris/handle/10665/250141, [accessed 24 September 2021]; Cohen, A.J., Brauer, M., Burnett, R., Anderson, H.R., Frostad, J., Estep, K., Balakrishnan, K., Forouzanfar, M.H., Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015 (2017) Lancet, 389. , 1907–1918; Du, Y., Xu, X., Chu, M., Guo, Y., Wang, J., Air particulate matter and cardiovascular disease: the epidemiological, biomedical and clinical evidence (2016) J Thorac Dis, 8, pp. E8-E19; Pope, C.A., 3rd, Dockery, D.W., Health effects of fine particulate air pollution: lines that connect (2006) J Air Waste Manag Assoc, 56, pp. 709-742; Brook, R.D., Rajagopalan, S., Pope, C.A., 3rd, Brook, J.R., Bhatnagar, A., Diez-Roux, A.V., Holguin, F., Kaufman, J.D., American Heart Association Council on Epidemiology and Prevention, Council on the Kidney in Cardiovascular Disease, and Council on Nutrition, Physical Activity and Metabolism. Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association (2010) Circulation, 121, pp. 2331-2378; Hoek, G., Brunekreef, B., Goldbohm, S., Fischer, P., van den Brandt, P.A., Association between mortality and indicators of traffic-related air pollution in the Netherlands: a cohort study (2002) The Lancet, 360, pp. 1203-1209; Pope, C.A., 3rd, Burnett, R.T., Thurston, G.D., Thun, M.J., Calle, E.E., Krewski, D., Godleski, J.J., Cardiovascular mortality and long-term exposure to particulate air pollution: epidemiological evidence of general pathophysiological pathways of disease (2004) Circulation, 109, pp. 71-77; Cohen, G., Steinberg, D.M., Keinan-Boker, L., Yuval, L.I., Chen, S., Shafran-Nathan, R., Levin, N., Gerber, Y., Preexisting coronary heart disease and susceptibility to long-term effects of traffic-related air pollution: a matched cohort analysis Eur J Prev Cardiol, , 2020. [Epub ahead of print]; Shah, A.S., Langrish, J.P., Nair, H., McAllister, D.A., Hunter, A.L., Donaldson, K., Newby, D.E., Mills, N.L., Global association of air pollution and heart failure: a systematic review and meta-analysis (2013) Lancet, 382, pp. 1039-1048; Atkinson, R.W., Carey, I.M., Kent, A.J., van Staa, T.P., Anderson, H.R., Cook, D.G., Original article: Long-term exposure to outdoor air pollution and the incidence of chronic obstructive pulmonary disease in a national English cohort (2015) Occup Environ Med, 72, p. 42. , –48; Bai, L., Shin, S., Burnett, R.T., Kwong, J.C., Hystad, P., van Donkelaar, A., Goldberg, M.S., Chen, H., Exposure to ambient air pollution and the incidence of congestive heart failure and acute myocardial infarction: A population-based study of 5.1 million Canadian adults living in Ontario (2019) Environ Int, 132, p. 105004; Bai, L., Weichenthal, S., Kwong, J.C., Burnett, R.T., Hatzopoulou, M., Jerrett, M., van Donkelaar, A., Chen, H., Associations of long-term exposure to ultrafine particles and nitrogen dioxide with increased incidence of congestive heart failure and acute myocardial infarction (2019) Am J Epidemiol, 188, pp. 151-159; Lam, C.S.P., Arnott, C., Beale, A.L., Chandramouli, C., Hilfiker-Kleiner, D., Kaye, D.M., Ky, B., Voors, A.A., Sex differences in heart failure (2019) Eur Heart J, 40, pp. 3859-3868c; Bragazzi, N.L., Zhong, W., Shu, J., Abu Much, A., Lotan, D., Grupper, A., Younis, A., Dai, H., Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017 (2021) Eur J Prev Cardiol, 28, pp. 1682-1690; Keates, A.K., Mocumbi, A.O., Ntsekhe, M., Sliwa, K., Stewart, S., Cardiovascular disease in Africa: epidemiological profile and challenges (2017) Nat Rev Cardiol, 14, pp. 273-293; Stewart, S., Carrington, M., Pretorius, S., Methusi, P., Sliwa, K., Standing at the crossroads between new and historically prevalent heart disease: effects of migration and socio-economic factors in the Heart of Soweto cohort study (2011) Eur Heart J, 32, pp. 492-499; Ogah, O.S., Sliwa, K., Akinyemi, J.O., Falase, A.O., Stewart, S., Hypertensive heart failure in Nigerian Africans: insights from the Abeokuta Heart Failure Registry (2015) J Clin Hypertens (Greenwich), 17, pp. 263-272; Damasceno, A., Mayosi, B.M., Sani, M., Ogah, O.S., Mondo, C., Ojji, D., Dzudie, A., Sliwa, K., The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries (2012) Arch Intern Med, 172, pp. 1386-1394; Fatema, N., Banerjee, S.K., Ahmed, C.M., Habib, A.A., Rahman, F., Ahsan, S.A., Hoque, H., Arzu, J., Clinical profile and outcome of peripartum cardiomyopathy - a study in a tertiary cardiac hospital of Bangladesh (2018) Mymensingh Med J, 27, pp. 298-303; Dokainish, H., Teo, K., Zhu, J., Roy, A., Karaye, K., Yusoff, K., Orlandini, A., Balasubramanian, K., Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study (2017) Lancet Glob Health, 5. , AlHabib KF, ElSayed A, Palileo-Villaneuva L, Lopez-Jaramillo P,, Islam S, Yacoub MH, Huffman MD, Harkness K, Grinvalds A, McKelvie R, Bangdiwala SI, Yusuf S;, e665–; , (2019). , https://population.un.org/wpp/Publications/Files/WPP2019_Highlights.pdf, Department of Economic and Social Affairs, Population Division. World Population Prospects 2019 Highlights. ST/ESA/SER.A/423, [accessed 28 September 2021]; Advancing into the golden years. Costs of healthcare for asia pacific's elderly, , https://www.marshmclennan.com/content/dam/mmc-web/insights/publications/2018/dec/healthy-societies/Advancing-into-the-Golden-Years/APRC%20Ageing%20report.pdf, Revision 2016., [accessed 24 September 2021]; Ohira, T., Iso, H., Cardiovascular disease epidemiology in Asia: an overview (2013) Circ J, 77, pp. 1646-1652; Shimokawa, H., Miura, M., Nochioka, K., Sakata, Y., Heart failure as a general pandemic in Asia (2015) Eur J Heart Fail, 17, pp. 884-892; Jiang, H., Ge, J., Epidemiology and clinical management of cardiomyopathies and heart failure in China (2009) Heart, 95, pp. 1727-1731; Sakata, Y., Shimokawa, H., Epidemiology of heart failure in Asia (2013) Circ J, 77, pp. 2209-2217; Lam, C.S.P., Heart failure in Southeast Asia: facts and numbers (2015) ESC Heart Fail, 2, pp. 46-49; Dalai, R., The Cost of Silence: Cardiovascular Disease in Asia. The Economist Intelligence Unit (EIU), , https://eiuperspectives.economist.com/sites/default/files/The_cost_of_silence.pdf, (28 Aug 2021); Lam, C.S., Teng, T.K., Tay, W.T., Anand, I., Zhang, S., Shimizu, W., Narasimhan, C., Richards, A.M., Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry (2016) Eur Heart J, 37, pp. 3141-3153; Reyes, E.B., Ha, J.W., Firdaus, I., Ghazi, A.M., Phrommintikul, A., Sim, D., Vu, Q.N., Cowie, M.R., Heart failure across Asia: same healthcare burden but differences in organization of care (2016) Int J Cardiol, 223, pp. 163-167; Grover, A., Vijayvergiya, R., Thingam, S.T., Burden of rheumatic and congenital heart disease in India: lowest estimate based on the 2001 census (2002) Indian Heart J, 54, pp. 104-107; Shiba, N., Nochioka, K., Miura, M., Kohno, H., Shimokawa, H., Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan--first report from the CHART-2 study (2011) Circ J, 75, pp. 823-833; Jones, J.Q., The Cost of Inaction: Secondary Prevention of Cardiovascular Disease in Asia-Pacific. The Economist Intelligence Unit (EIU), , https://eiuperspectives.economist.com/sites/default/files/eiu_amgen_cvd_secondary_prevention_whitepaper_0319.pdf, (28 August 2021); (2018) National Health Survey: First Results, 2017–18 Financial Year j Australian Bureau of Statistics, , https://www.abs.gov.au/statistics/health/health-conditions-and-risks/national-health-survey-first-results/latest-release, (28 August 2021); Chan, Y.K., Tuttle, C., Ball, J., Teng, T.K., Ahamed, Y., Carrington, M.J., Stewart, S., Current and projected burden of heart failure in the Australian adult population: a substantive but still ill-defined major health issue (2016) BMC Health Serv Res, 16, p. 501; Abhayaratna, W.P., Smith, W.T., Becker, N.G., Marwick, T.H., Jeffery, I.M., McGill, D.A., Prevalence of heart failure and systolic ventricular dysfunction in older Australians: the Canberra Heart Study (2006) Med J Aust, 184, pp. 151-154; McGrady, M., Krum, H., Carrington, M.J., Stewart, S., Zeitz, C., Lee, G.A., Marwick, T.H., Brown, A., Heart failure, ventricular dysfunction and risk factor prevalence in Australian Aboriginal peoples: the Heart of the Heart Study (2012) Heart, 98, pp. 1562-1567; Ponikowski, P., Anker, S.D., AlHabib, K.F., Cowie, M.R., Force, T.L., Hu, S., Jaarsma, T., Filippatos, G., Heart failure: preventing disease and death worldwide (2014) ESC Heart Fail, 1, pp. 4-25; Ferreira, J.P., Kraus, S., Mitchell, S., Perel, P., Piñeiro, D., Chioncel, O., Colque, R., Sliwa, K., World Heart Federation roadmap for heart failure (2019) Glob Heart, 14, pp. 197-214; Scharge, B., Geelhoed, B., Niiranen, T.J., Gianfagna, F., Vishram-Nielsen, J.K.K., Costanzo, S., Söderberg, S., Schnabel, R.B., Comparison of cardiovascular risk factors in European Population cohorts for predicting atrial fibrillation and heart failure, their subsequent onset, and death (2020) J Am Heart Assoc, 9; Magnussen, C., Niiranen, T.J., Ojeda, F.M., Gianfagna, F., Blankenberg, S., Vartiainen, E., Sans, S., Schnabel, R.B., Sex-specific epidemiology of heart failure risk and mortality in Europe: results from the BiomarCaRE Consortium (2019) JACC Heart Fail., 7, pp. 204-213; Uijl, A., Koudstaal, S., Vaartjes, I., Boer, J.M.A., Verschuren, W.M.M., van der Schouw, Y.T., Asselbergs, F.W., Sluijs, I., Risk for heart failure: the opportunity for prevention with the American Heart Association's Life's Simple 7 (2019) JACC Heart Fail., 7, pp. 637-647; Pujades-Rodriguez, M., George, J., Shah, A.D., Rapsomaniki, E., Denaxas, S., West, R., Smeeth, L., Hemingway, H., Heterogeneous associations between smoking and a wide range of initial presentations of cardiovascular disease in 1937360 people in England: lifetime risks and implications for risk prediction (2015) Int J Epidemiol, 44, pp. 129-141; Baena-Díez, J.M., Byram, A.O., Grau, M., Gómez-Fernández, C., Vidal-Solsona, M., Ledesma-Ulloa, G., González-Casafont, I., Schroder, H., Obesity is an independent risk factor for heart failure: Zona Franca Cohort study (2010) Clin Cardiol, 33, pp. 760-764; Lawson, C.A., Zaccardi, F., Squire, I., Okhai, H., Davies, M., Huang, W., Mamas, M., Kadam, U.T., Risk factors for heart failure: 20-year population-based trends by sex, socioeconomic status, and ethnicity (2020) Circ Heart Fail, 13; Conrad, N., Judge, A., Tran, J., Mohseni, H., Hedgecott, D., Crespillo, A.P., Allison, M., Rahimi, K., Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals (2018) Lancet, 391, pp. 572-580; Van Deursen, V.M., Urso, R., Laroche, C., Damman, K., Dahlström, U., Tavazzi, L., Maggioni, A.P., Voors, A.A., Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey (2014) Eur J Heart Fail, 16, pp. 103-111; Iorio, A., Senni, M., Barbati, G., Greene, S.J., Poli, S., Zambon, E., Di Nora, C., Di Lenarda, A., Prevalence and prognostic impact of non-cardiac co- morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study (2018) Eur J Heart Fail, 20, pp. 1257-1266; Christiansen, M.N., Køber, L., Torp-Pedersen, C., Gislason, G.H., Schou, M., Smith, J.G., Vasan, R.S., Andersson, C., Preheart failure comorbidities and impact on prognosis in heart failure patients: a nationwide study (2020) J Intern Med, 287, pp. 698-710; Chioncel, O., Lainscak, M., Seferovic, P.M., Anker, S.D., Crespo-Leiro, M.G., Harjola, V.P., Parissis, J., Filippatos, G., Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry (2017) Eur J Heart Fail, 19, pp. 1574-1585; Blair, J.E., Huffman, M., Shah, S.J., Heart failure in North America (2013) Curr Cardiol Rev, 9, pp. 128-146; Glynn, P., Ning, H., Bavishi, A., Shah, S., Yancy, C., Jones, D.L., Khan, S., Heart failure risk distribution and trends in the united states population from 1999–2014: results frm health and nutrition examination survey (2019) J Am Coll Cardiol, 73. , 785 (abstr); Virani, S.S., Alonso, A., Benjamin, E.J., Bittencourt, M.S., Callaway, C.W., Carson, A.P., Chamberlain, A.M., Tsao, C.W., Heart Disease and Stroke Statistics-2020 Update: a report from the American Heart Association (2020) Circulation, 141. , e139–; Heidenreich, P.A., Albert, N.M., Allen, L.A., Bluemke, D.A., Butler, J., Fonarow, G.C., Ikonomidis, J.S., Trogdon, J.G., Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association (2013) Circ Heart Fail, 6, pp. 606-619; (2017) Heart Disease in Canada: Highlights from the Canadian Chronic Disease Surveillance System, 2017-Canada.ca. Public Health Agency of Canada, , https://www.canada.ca/en/public-health/services/publications/diseases-conditions/heart-disease-canada-fact-sheet.html, (28 Aug 2021); Yeung, D.F., Boom, N.K., Guo, H., Lee, D.S., Schultz, S.E., Tu, J.V., Trends in the incidence and outcomes of heart failure in Ontario, Canada: 1997 to 2007 (2012) CMAJ, 184, pp. E765-E773; Padwal, R.S., Bienek, A., McAlister, F.A., Campbell, N.R., Outcomes research task force of the Canadian hypertension education program. Epidemiology of hypertension in Canada: an update (2016) Can J Cardiol, 32, pp. 687-694; Daskalopoulou, S.S., Rabi, D.M., Zarnke, K.B., Dasgupta, K., Nerenberg, K., Cloutier, L., Gelfer, M., Padwal, R.S., The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension (2015) Can J Cardiol, 31, pp. 549-568; Whelton, P.K., Carey, R.M., Aronow, W.S., Casey, D.E., Jr., Collins, K.J., Dennison Himmelfarb, C., DePalma, S.M., Wright, J.T., Jr., 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines (2018) Hypertension, 71, pp. 1269-1324; Wright, J.T., Jr., Williamson, J.D., Whelton, P.K., Snyder, J.K., Sink, K.M., Rocco, M.V., Reboussin, D.M., Ambrosius, W.T., A randomized trial of intensive versus standard blood-pressure control (2015) N Engl J Med, 373, pp. 2103-2116; Feely, A., Lix, L.M., Reimer, K., Estimating multimorbidity prevalence with the Canadian Chronic Disease Surveillance System (2017) Health Promot Chronic Dis Prev Can, 37, pp. 215-222; Ruilope, L.M., Nunes Filho, A.C.B., Nadruz, W., Jr., Rodríguez Rosales, F.F., Verdejo-Paris, J., Obesity and hypertension in Latin America: current perspectives (2018) Hipertens Riesgo Vasc, 35, pp. 70-76; Seron, P., Irazola, V., Rubinstein, A., Calandrelli, M., Ponzo, J., Olivera, H., Gutierrez, L., Lanas, F., Ideal Cardiovascular Health in the southern cone of Latin America (2018) Public Health, 156, pp. 132-139; Ciapponi, A., Alcaraz, A., Calderón, M., Matta, M.G., Chaparro, M., Soto, N., Bardach, A., Burden of heart failure in Latin America: a systematic review and meta-analysis (2016) Rev Esp Cardiol (Engl Ed), 69, pp. 1051-1060; Van Riet, E.E., Hoes, A.W., Wagenaar, K.P., Limburg, A., Landman, M.A., Rutten, F.H., Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review (2016) Eur J Heart Fail, 18, pp. 242-252; Echeverría, L.E., Marcus, R., Novick, G., Sosa-Estani, S., Ralston, K., Zaidel, E.J., Forsyth, C., Molina, G.R., WHF IASC Roadmap on Chagas disease (2020) Glob Heart, 15, p. 26
PY - 2022
Y1 - 2022
N2 - The heart failure epidemic is growing and its prevention, in order to reduce associated hospital readmission rates and its clinical and economic burden, is a key issue in modern cardiovascular medicine. The present position paper aims to provide practical evidence-based information to support the implementation of effective preventive measures. After reviewing the most common risk factors, an overview of the population attributable risks in different continents is presented, to identify potentially effective opportunities for prevention and to inform preventive strategies. Finally, potential interventions that have been proposed and have been shown to be effective in preventing heart failure are listed. The article has been co-published with permission in the European Journal of Preventive Cardiology and European Journal of Heart Failure. All rights reserved. © the Author(s) 2022. The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article.
AB - The heart failure epidemic is growing and its prevention, in order to reduce associated hospital readmission rates and its clinical and economic burden, is a key issue in modern cardiovascular medicine. The present position paper aims to provide practical evidence-based information to support the implementation of effective preventive measures. After reviewing the most common risk factors, an overview of the population attributable risks in different continents is presented, to identify potentially effective opportunities for prevention and to inform preventive strategies. Finally, potential interventions that have been proposed and have been shown to be effective in preventing heart failure are listed. The article has been co-published with permission in the European Journal of Preventive Cardiology and European Journal of Heart Failure. All rights reserved. © the Author(s) 2022. The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article.
KW - cardiology
KW - heart failure
KW - human
KW - risk factor
KW - Cardiology
KW - Heart Failure
KW - Humans
KW - Risk Factors
UR - https://doi.org/10.25905/21825057.v1
U2 - 10.1002/ejhf.2351
DO - 10.1002/ejhf.2351
M3 - Article
SN - 1388-9842
VL - 24
SP - 143
EP - 168
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 1
ER -